Appearance of Thrombogenic Tendency Induced by Adrenaline and Its Prevention by β-Adrenergic Blocking Agent, Nialamide and Pyridinolcarbamate

Summary

In 52 men and 33 women, the total, adhesive and nonadhesive platelet counts, onestage prothrombin time, euglobulinlysis time, and plasma nonesterified fatty acid were measured before and after an intravenous injection with 0.1 μg/kg of adrenaline or 1-noradrenaline. Three hours before the injection, placebo, 30 mg of phenoxybenzamine, 300 mg of pronethalol, 100 mg of nialamide or 100 mg of pyridinolcarbamate was administered orally under the double blind technique. Five minutes after the injection with adrenaline in 15 cases pretreated with placebo, a decrease in adhesive platelet count, and a shortening of one-stage prothrombin time and euglobulin lysis time were observed with statistical significance (P ˂ 0.01 ∼ 0.05). These changes were not observed in 15 cases injected with saline or noradrenaline. The changes were not observed in 10 cases pretreated with pronethalol, but were observed in 10 cases pretreated with phenoxybenzamine. So the effect of adrenaline may be due to stimulation of ß-adrenergic receptor sites. Meanwhile, the decrease in adhesive platelet count and the enhancement of blood coagulability were prevented by nialamide and pyridinolcarbamate, while the enhancement of fibrinolysis was not. The preventive effect of nialamide was less than that of pyridinolcarbamate. Phenoxybenzamine and nialamide prevented an increase in systolic blood pressure induced by adrenaline, and pronethalol prevented tachycardia by adrenaline, while pyridinolcarbamate did not affect these changes. Changes in plasma nonesterified fatty acid showed no relationship to the above hematological changes.

• References

• 1 Apthorp G. H, Chamberlain D. A, Hayward G. W. Th© effects of sympathectomy on the electrocardiogram and effort tolerance in angina pectoris. Brit. Heart J 26: 218 1964;
• 2 Biggs R, Macfarlane R. G, Pilling J. Observations on fibrinolysis. Experimental activity produced by exercise or adrenaline. Lancet I: 402 1947;
• 3 Black J. W, Stephenson J. S. Pharmacology of a new adrenergic beta-receptor blocking compound (Nethalide). Lancet II: 311 1962;
• 4 Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J. clin. Path 11: 403 1958;
• 5 Gannon W. B. The wisdom of the body. W. W. Norton; New York 1939.:
• 6 Hosaki S, Anan K, Nakao M, Shimamoto T. Gas-liquid chromatographic study of plasma nonesterified fatty acid by the BF₃esterification method. J. Jap. Biochem. Soc 35: 619 1963;
• 7 Kwaan H. C, Lo R, McFadzean A. G. S. On the production of plasma fibrinolytic activity within veins. Clin. Sci 16: 241 1957;
• 8 Macfarlane R. G, Biggs R. Observations on fibrinolysis. Spontaneous activity associated with surgical operations, trauma, etc. Lancet II: 862 1946;
• 9 McKay D. G, Latour J. G, Parrish II M. Activation of Hageman factor by a-adrenergic stimulation. Thrombos. Diathes. haemorrh. (Stuttg) 23: 417 1970;
• 10 Moolten S. E, Vroman L. The adhesiveness of blood platelets in thromboembolism and hemorrhagic disorders. I. Measurement of platelet adhesiveness by the glass-wool filter. Amer. J. clin. Path 19: 701 1949;
• 11 Olef I. The enumeration of blood platelets. J. Lab. clin. Med 20: 416 1935;
• 12 Quick A. J. Determination of prothrombin. Amer. J. med. Sci 190: 501 1935;
• 13 Sano T. An immediate and transient thrombocytopenic reaction by adrenaline. Jap. J . intern. Med 52: 1213 1964;
• 14 Shafrir E, Steinberg D. The essential role of the adrenal cortex in the response of plasma free fatty acids, cholesterol, and phospholipids to epinephrine injection. J. clin. Invest 39: 310 1960;
• 15 Sherry S, Lindemeyer E. I, Fletcher A. P, Alkjaersig N. Studies on enhanced fibrinolytic activity in man. J. clin. Invest 38: 810 1959;
• 16 Shimamoto T, Yamazaki H, Inoue M, Fujita T, Sagawa N, Ishioka T. Sunaga: Effect of adrenaline and noradrenaline on “silicone-like property” of blood vessels. Proc. Jap. Acad 36: 234 1960;
• 17 Shimamoto T, Yamazaki H, Tsuchihashi H, Ishioka T. MAO inhibitor, nialamide, a new type of anti-thrombotic substance in vascular, especially cardiovascular disorder. Asian med. J 04: 5 1961;
• 18 Shimamoto T, Ishioka T, Fujita T. Antithrombotic effect of monoamine oxidase inhibitor (nialamide). Circulât. Res 10: 647 1962;
• 19 Shimamoto T. The relationship of edematous reaction in arteries to atherosclerosis and thrombosis. J. Atheroscler. Res 03: 87 1963;
• 20 Shimamoto T. New type antithrombotic treatment of myocardial infarction. Jap. Circulât. J 27: 187 1963;
• 21 Shimamoto T, Ishioka T. Release of a thromboplastic substance from arterial walls by epinephrine. Circulât. Res 12: 138 1963;
• 22 Shimamoto T, Maezawa H, Yamazaki H, Atsumi T, Fujita T, Ishioka T, Sunaga T. Pyridinolcarbamate, a bradykinin antagonist in veins - a preliminary report on pharmacologic and clinical observation. Amer. Heart. J 71: 297 1966;
• 23 Shimamoto T, Maezawa H, Yamazaki H, Ishioka T, Sunaga T, Fujita T. Edematous arterial reaction and its relationship to atherosclerosis and thrombosis. In: Meth. Achievm. exp. Path. Ed. by Bajusz E, Jasmin G. Vol. 1 337 S. Karger; Basei/New York 1966.:
• 24 Truelove S. C. Fibrinolysis and eosinophil count. Clin. Sei 10: 229 1951;
• 25 Yamazaki H, Sano T, Odakura T, Takeuchi K, Shimamoto T. Electrocardiographic and hematological changes by exercise test in coronary patients and pyridinolcarbamate pretreatment. A double-blind crossover trial. Amer. Heart J 79: 640 1970;
• 26 Yamazaki H, Odakura T, Takeuchi K, Sano T. Adhesive platelet count and blood coagulability in myocardial infarction and cerebral thrombosis. Thrombos. Diathes. haemorrh. (Stuttg) 24: 450 1970;